危重患者炎症的营养与代谢调控:理由、证据与灰色地带的叙述性综述
本叙述性综述阐述危重病炎症触发神经内分泌应激反应和氧化应激,持续或过度炎症与高代谢、高分解代谢相关,影响短期和长期功能状态、自主性及健康相关费用。炎症调控策略包括肠内营养启动时机、特定宏量/微量营养素、益生菌及代谢治疗。n-3多不饱和脂肪酸、维生素D、抗氧化微量营养素和普萘洛尔因安全性、临床可及性及在重症临床研究中的获益而最受关注,但多数最佳剂量、时机和给药途径未知,恢复期应用研究不足。严重烧伤患者的研究结果需谨慎外推至非烧伤患者,需进一步研究炎症调控如何改善危重病后长期结局。
要点
- 危重病炎症触发神经内分泌应激反应和氧化应激,持续或过度炎症与高代谢、高分解代谢相关,影响短期和长期功能状态、自主性及健康相关费用。
- n-3多不饱和脂肪酸、维生素D、抗氧化微量营养素和普萘洛尔因安全性、临床可及性及重症临床研究中的获益而较有前景。
- 多数炎症调控策略的最佳剂量、时机和给药途径仍未知,恢复期应用研究不足。
- 严重烧伤患者的研究结果外推至非烧伤患者需谨慎。
- 炎症调控的临床研究证据并不总是充分,需进一步研究其如何改善危重病后长期结局。
适用人群与场景
- 危重病患者,包括严重烧伤患者;非烧伤危重患者外推严重烧伤研究结果需谨慎。
处置流程与药物剂量
- 营养策略包括肠内营养启动时机、提供特定宏量营养素或微量营养素、使用益生菌;代谢治疗包括n-3多不饱和脂肪酸、维生素D、抗氧化微量营养素和普萘洛尔,但多数最佳剂量、时机和给药途径仍未知。
研究设计与关键结果
- 叙述性综述:炎症可由营养策略(肠内营养启动时机、特定宏量/微量营养素、益生菌)和代谢治疗调控;n-3多不饱和脂肪酸、维生素D、抗氧化微量营养素和普萘洛尔因安全性、临床可及性及重症临床研究中的获益而最受关注;多数最佳剂量、时机和给药途径仍未知,恢复期应用研究不足;严重烧伤患者的研究结果外推至非烧伤患者需谨慎;需进一步研究炎症调控如何改善危重病后长期结局。
证据类型、等级与局限
- 证据类型:叙述性综述;局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,基于危重病病理生理学及某些营养和药理策略日益被描述的作用,使用炎症调控策略的理由显而易见;但临床研究并不总是提供炎症调控直接带来积极影响的充分证据;严重烧伤患者的研究结果外推至非烧伤患者需谨慎;需进一步研究炎症调控如何改善危重病后长期结局。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Inflammation is the hallmark of critical illness and triggers the neuro-endocrine stress response and an oxidative stress. Acute inflammation is initially essential for patient's survival. However, ongoing or exaggerated inflammation, due to persistent organ dysfunction, immune dysfunction or poor inflammation resolution, is associated to subsequent hypermetabolism and hypercatabolism that severely impact short and long-term functional status, autonomy, as well as health-related costs. Modulation of inflammation is thus tempting, with the goal to improve the short- and long-term outcomes of critically ill patients.
FINDINGS: Inflammation can be modulated by nutritional strategies (including the timing of enteral nutrition initiation, the provision of some specific macronutrients or micronutrients, the use of probiotics) and metabolic treatments. The most interesting strategies seem to be n-3 polyunsaturated fatty acids, vitamin D, antioxidant micronutrients and propranolol, given their safety, their accessibility for clinical use, and their benefits in clinical studies in the specific context of critical care. However, the optimal doses, timing and route of administration are still unknown for most of them. Furthermore, their use in the recovery phase is not well studied and defined.
CONCLUSION: The rationale to use strategies of inflammation modulation is obvious, based on critical illness pathophysiology and based on the increasingly described effects of some nutritional and pharmacological strategies. Regretfully, there isn't always substantial proof from clinical research regarding the positive impacts directly brought about by inflammation modulation. Some arguments come from studies performed in severe burn patients, but such results should be transposed to non-burn patients with caution. Further studies are needed to explore how the modulation of inflammation can improve the long-term outcomes after a critical illness.
参考来源
- Rousseau AF, Martindale R. Nutritional and metabolic modulation of inflammation in critically ill patients: a narrative review of rationale, evidence and grey areas. Ann Intensive Care. 2024. PMID: 39088114. doi:10.1186/s13613-024-01350-x
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。